
Cahill Represents Debt Financing Sources in \$2.15 Billion of Debt Financings for Embecta Corp., Consisting of \$700 Million of Notes Offerings, a \$200 Million Tender Offer and \$1.45 Billion of Credit Facilities

Date: 04/01/22

Cahill represented the initial purchasers in connection with two Rule 144A offerings by Embecta Corp., consisting of \$500,000,000 aggregate principal amount of 5.000% senior secured notes due 2030 and \$200,000,000 aggregate principal amount of 6.750% senior secured notes due 2030 and represented the offeror in connection with a \$200 million tender offer by Morgan Stanley for Becton, Dickinson and Company's existing notes. Cahill also represented the lead arrangers in connection with a \$950,000,000 term B credit facility and a \$500,000,000 revolving credit facility for Embecta Corp. Proceeds from the offerings and the credit facilities were used (i) to fund a dividend to Becton, Dickinson and Company in connection with the spin-off transaction of Embecta Corp. from Becton, Dickinson and Company, (ii) to pay fees and expenses relating to the debt financings and the contemplated spin-off transaction, and (iii) for general corporate purposes. Embecta Corp. is a global medical device company focused on the diabetes care business.

Attorneys

- Meghan McDermott
- Josiah M. Slotnick
- Matthew Flores
- Alexa S. Kaminsky
- Conor R. Rigsby
- Steven D. Seiden
- Spencer Shweky
- Michael Wolynski